VolitionRx Limited Other Comprehensive Income (Loss), Net of Tax
VolitionRx Limited (VNRX) reported Other Comprehensive Income (Loss), Net of Tax of -$7.74 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2022-11-14
- VolitionRx Limited other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$7.74M.
- VolitionRx Limited other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$7.52M.
- VolitionRx Limited other comprehensive income (loss), net of tax for the quarter ending 2022-03-31 was -$7.84M.
- VolitionRx Limited other comprehensive income (loss), net of tax for the quarter ending 2021-12-31 was -$7.97M.
- VolitionRx Limited other comprehensive income (loss), net of tax for fiscal 2021 was -$26.78M.
- VolitionRx Limited other comprehensive income (loss), net of tax for fiscal 2020 was -$20.58M.
- VolitionRx Limited other comprehensive income (loss), net of tax for fiscal 2019 was -$16.20M.
- VolitionRx Limited other comprehensive income (loss), net of tax for fiscal 2018 was -$17.66M, a 27706.76% decline from fiscal 2017.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 17 month |
|---|---|---|---|---|---|---|
| 2022-09-30 | -$7.74M 10-Q · filed 2022-11-14 | -$15.26M derived: sum of 2 quarters · filed 2022-11-14 | -$23.10M 10-Q · filed 2022-11-14 | -$31.06M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2022-06-30 | -$7.52M 10-Q · filed 2022-08-10 | -$15.35M 10-Q · filed 2022-08-10 | -$23.32M derived: sum of 3 quarters · filed 2022-08-10 | -$30.52M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2022-03-31 | -$7.84M 10-Q · filed 2022-05-11 | -$15.80M derived: sum of 2 quarters · filed 2022-05-11 | -$23.01M derived: sum of 3 quarters · filed 2022-11-14 | -$28.63M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-12-31 | -$7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$15.17M derived: sum of 2 quarters · filed 2022-11-14 | -$20.79M derived: sum of 3 quarters · filed 2022-11-14 | -$26.78M 10-K · filed 2022-03-30 | ||
| 2021-09-30 | -$7.20M 10-Q · filed 2022-11-14 | -$12.82M derived: sum of 2 quarters · filed 2022-11-14 | -$18.81M 10-Q · filed 2022-11-14 | -$23.89M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$5.62M 10-Q · filed 2022-08-10 | -$11.61M 10-Q · filed 2022-08-10 | -$16.68M derived: sum of 3 quarters · filed 2022-08-10 | -$21.59M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | -$5.99M 10-Q · filed 2022-05-11 | -$11.06M derived: sum of 2 quarters · filed 2022-05-11 | -$15.97M derived: sum of 3 quarters · filed 2022-05-11 | -$21.09M derived: sum of 4 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$9.98M derived: sum of 2 quarters · filed 2022-03-30 | -$15.10M derived: sum of 3 quarters · filed 2022-03-30 | -$20.58M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$4.91M 10-Q · filed 2021-11-10 | -$10.03M derived: sum of 2 quarters · filed 2021-11-10 | -$15.51M 10-Q · filed 2021-11-10 | -$19.59M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | -$5.12M 10-Q · filed 2021-08-11 | -$10.60M 10-Q · filed 2021-08-11 | -$14.69M derived: sum of 3 quarters · filed 2021-08-11 | -$18.46M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | -$5.49M 10-Q · filed 2021-05-11 | -$9.57M derived: sum of 2 quarters · filed 2021-05-11 | -$13.35M derived: sum of 3 quarters · filed 2021-05-11 | -$17.45M derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$7.86M derived: sum of 2 quarters · filed 2021-03-22 | -$11.97M derived: sum of 3 quarters · filed 2021-03-22 | -$16.20M 10-K · filed 2021-03-22 | ||
| 2019-09-30 | -$3.78M 10-Q · filed 2020-11-12 | -$7.89M derived: sum of 2 quarters · filed 2020-11-12 | -$12.11M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$4.11M 10-Q · filed 2020-08-13 | -$8.34M 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | -$4.23M 10-Q · filed 2020-05-07 | -$24.05K 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | -$17.66M 10-K · filed 2020-02-20 | |||||
| 2018-03-31 | $14.95K 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | $63.95K 10-K · filed 2018-03-01 | |||||
| 2016-12-31 | -$109.13K 10-K · filed 2018-03-01 | |||||
| 2015-12-31 | $19.66K 10-K · filed 2017-03-10 | |||||
| 2014-12-31 | -$44.04K 10-K · filed 2016-03-11 | |||||
| 2013-12-31 | -$25.52K 10-K · filed 2015-03-18 | |||||
| 2012-12-31 | -$38.91K 10-K · filed 2014-03-28 | |||||
| 2011-12-31 | $4.64K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |